临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2014年
20期
12-14
,共3页
胰岛素%糖尿病%并发症%低血糖%危症
胰島素%糖尿病%併髮癥%低血糖%危癥
이도소%당뇨병%병발증%저혈당%위증
Insulin%Diabetes mellitus%Complication%Hypoglycemia%Critical illness
目的:胰岛素是常用降血糖注射剂。本文旨在分析胰岛素治疗的风险,为临床治疗提供参考。方法临床研究包括2型糖尿病(T2Dm)患者和危症患者。前瞻性研究观察华人 T2Dm 2906例(其中胰岛素治疗971例),连续随访7年。横断面资料研究中美国 T2Dm 25964例,英国 T2Dm 84622例。死亡、癌症、慢性并发症、低血糖与危症是主要临床终点。结果胰岛素治疗显著增加 T2Dm 临床终点事件风险:死亡( HR =2.2;95% CI =2.0-2.4),癌症(HR =1.4;95% CI =1.2-1.7),肾病(HR =3.5;95% CI =2.7-4.5),心肌梗死(HR =2.0;95% CI =1.5-2.6),主要不良心脏事件(HR =1.7;95% CI =1.4-2.1),中风(HR =1.4;95% CI =1.2-1.8)。胰岛素治疗的危症患者6026例,出现低血糖,其死亡风险呈线性升高:中度低血糖组 HR =1.4,95% CI =1.2-1.6;严重性低血糖组 HR =2.1,95% CI =1.6-2.8。结论糖尿病患者及危症患者应慎用胰岛素治疗,胰岛素治疗的系统风险不容低估。
目的:胰島素是常用降血糖註射劑。本文旨在分析胰島素治療的風險,為臨床治療提供參攷。方法臨床研究包括2型糖尿病(T2Dm)患者和危癥患者。前瞻性研究觀察華人 T2Dm 2906例(其中胰島素治療971例),連續隨訪7年。橫斷麵資料研究中美國 T2Dm 25964例,英國 T2Dm 84622例。死亡、癌癥、慢性併髮癥、低血糖與危癥是主要臨床終點。結果胰島素治療顯著增加 T2Dm 臨床終點事件風險:死亡( HR =2.2;95% CI =2.0-2.4),癌癥(HR =1.4;95% CI =1.2-1.7),腎病(HR =3.5;95% CI =2.7-4.5),心肌梗死(HR =2.0;95% CI =1.5-2.6),主要不良心髒事件(HR =1.7;95% CI =1.4-2.1),中風(HR =1.4;95% CI =1.2-1.8)。胰島素治療的危癥患者6026例,齣現低血糖,其死亡風險呈線性升高:中度低血糖組 HR =1.4,95% CI =1.2-1.6;嚴重性低血糖組 HR =2.1,95% CI =1.6-2.8。結論糖尿病患者及危癥患者應慎用胰島素治療,胰島素治療的繫統風險不容低估。
목적:이도소시상용강혈당주사제。본문지재분석이도소치료적풍험,위림상치료제공삼고。방법림상연구포괄2형당뇨병(T2Dm)환자화위증환자。전첨성연구관찰화인 T2Dm 2906례(기중이도소치료971례),련속수방7년。횡단면자료연구중미국 T2Dm 25964례,영국 T2Dm 84622례。사망、암증、만성병발증、저혈당여위증시주요림상종점。결과이도소치료현저증가 T2Dm 림상종점사건풍험:사망( HR =2.2;95% CI =2.0-2.4),암증(HR =1.4;95% CI =1.2-1.7),신병(HR =3.5;95% CI =2.7-4.5),심기경사(HR =2.0;95% CI =1.5-2.6),주요불양심장사건(HR =1.7;95% CI =1.4-2.1),중풍(HR =1.4;95% CI =1.2-1.8)。이도소치료적위증환자6026례,출현저혈당,기사망풍험정선성승고:중도저혈당조 HR =1.4,95% CI =1.2-1.6;엄중성저혈당조 HR =2.1,95% CI =1.6-2.8。결론당뇨병환자급위증환자응신용이도소치료,이도소치료적계통풍험불용저고。
Objective Insulin is widely use for the control of blood glucose. Hereby we evaluated the hazards of insu-lin treatment to provide the reference for the clinical treatment. Methods Data were extracted from 5 clinical studies of sub-jects with type 2 diabetes(T2Dm)and patients with critical illness. Prospective controlled trial involved 2906 Chinese T2Dm persons(insulin users,971)followed up to 7 years. Two more T2Dm cohorts were from USA( n = 25964)and UK( n =84622)conducted by cross-sectional analysis. major clinical endpoints included all-cause mortality,all - site cancer,chronic complication,and severe hypoglycemia. Results Use of insulin injection substantially increased the hazard risk(HR)of all the major clinical endpoints:all cause mortality(HR = 2. 2;95% CI = 2. 0 - 2. 4),cancer(HR = 1. 4;95% CI = 1. 2 - 1. 7), renal complication(HR = 3. 5;95% CI = 2. 7 - 4. 5),myocardial infarction(HR = 2. 0;95% CI = 1. 5 - 2. 6),major adverse cardiac events(HR = 1. 7;95% CI = 1. 4 - 2. 1),stroke(HR = 1. 4;95% CI = 1. 2 - 1. 8). 6026 critically ill patients showed linear HR of death with insulin - induced moderate hypoglycemia(HR = 1. 4,95% CI = 1. 2 - 1. 6)or severe hypoglycemia (HR = 2. 1,95% CI = 1. 6 - 2. 8). Conclusions Patients with diabetes or critical illness should be cautious about using insu-lin. The system hazard risk of using insulin is generally underestimated.